
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
What’s the best way to reach first-in-man studies when you have little to no information? Bioavailability issues, financial constraints.
What’s the best way to reach first-in-man studies when you have little to no information? Bioavailability issues, financial constraints, and pressure to meet accelerated deadlines can affect development, so having a firm plan in place is key. PharmTech is hosting a free educational






